Amend 005 - Hepatitis A and B Adult and Pediatric - GlaxoSmithKline Inc.
Contract number E60PH-22HEAB/001/PH
Amendment value : CAD 3,788,170.93
Solicitation number E60PH-22HEAB
Contract award date
Expiry date
Amendment date
Contract number E60PH-22HEAB/001/PH
Amendment value : CAD 3,788,170.93
Solicitation number E60PH-22HEAB
Contract award date
Expiry date
Amendment date
The contract will be for a period of 36 month(s), from 2022/03/03 to 2025/03/31.
This is the total value of this contract, which includes the initial contract value and the sum of all amendments.
CAD 17,340,563.63
A contracting officer can use limited tendering for specific reasons outlined in the applicable trade agreements. The reason for this contract is described below: